INTRODUCTION
Neuroblastoma is a malignancy of early childhood that arises from the developing autonomic nervous system (Maris et al., 2007) . It is the most frequently diagnosed cancer in the first year of life and shows a remarkably heterogeneous clinical behavior. Some tumors regress spontaneously, whereas others progress to highly aggressive metastatic disease with a poor overall survival rate. Amplification of the MYCN oncogene and/ or loss of the chromosomal regions 1p36 and 11q23 correlate with poor disease outcome (Attiyeh et al., 2005; Caron et al., 1996; Seeger et al., 1985) . Recurrent gene mutations are relatively rare in neuroblastoma. Somatic and germline activating mutations in the ALK kinase have been identified in 7% of neuroblastomas, providing the basis for a promising molecular targeted therapy in this subgroup (reviewed in Mosse et al., 2009) . PHOX2B and PTPN11 mutations were found in 2% and 3% of neuroblastomas, respectively (Bentires-Alj et al., 2004; van Limpt et al., 2004) .
Neuroblastomas frequently transdifferentiate into more benign ganglioneuroblastomas and ganglioneuromas. Progression in the opposite direction is also observed in patients. The vitamin A metabolite retinoic acid (RA) is an important morphogen for the developing nervous system in vivo and capable of differentiating neuronal cells in vitro (Duester, 2008) . Various neuroblastoma cell lines cease proliferation, differentiate into neuronallike cells, or undergo apoptosis upon exposure to RA (Sidell et al., 1983) . These observations established the basis for the clinical application of RA in the treatment of neuroblastoma. RA is one of the few targeted therapeutics currently used in the clinic for aggressive neuroblastoma, but the benefit is limited. A phase III randomized trial showed that treatment with 13-cis-RA given after completion of intensive chemoradiotherapy yields a slight but significant improvement in event-free survival in high-risk neuroblastoma (Matthay et al., 1999 (Matthay et al., , 2009 ).
The physiological functions of retinoids are primarily exerted through the regulation of specific target genes mediated by retinoid acid receptors (RARs). RARs are nuclear hormone receptors that function as ligand-dependent transcription factors (reviewed in Rochette-Egly and Germain, 2009) . Their activity requires heterodimerization with the retinoid X receptors (RXRs) that can also associate with several other nuclear hormone receptors. RAR/RXR heterodimers constitutively bind to retinoic acid response elements (RAREs) in the promoter regions of target genes and actively repress transcription in the absence of ligand. This process involves recruitment of the corepressors NCoR and SMRT and histone deacetylases (HDACs) . RA binds to RAR and triggers conformational changes that release the corepressors and in turn promote the assembly of coactivator complexes. Subsequently, transcription of target genes is initiated. Many of the coactivators, including CBP/ p300, PCAF, and SRC1-3 (NCOA1-3), possess histone acetylase (HAT) activity that promotes transactivation of RAR/RXR. In contrast, ligand-dependent corepressors such as LCoR and PRAME recruit HDACs or PcG proteins to ligand-bound RAR/ RXR complexes to repress their activities (Epping et al., 2005; Fernandes et al., 2003) . Therefore, co-activators/repressors play crucial roles for the context-dependent action of RA and may be important determinants and biomarkers for RA-based therapies in the clinic.
Recently, we have used a large-scale RNA interference (RNAi) based screen in F9 mouse teratocarcinoma cells, a widely used model system to study RA signaling (Huang et al., 2009) , to identify ZNF423 as a critical cofactor required for RAR/RXR function. We found that ZNF423 is also crucial for RA-mediated growth arrest and differentiation in human neuroblastoma cell lines and that its reduced expression was a powerful marker of poor prognosis in neuroblastoma patients, independent of MYCN amplification. However, we have not observed loss of heterozygosity at the ZNF423 locus in primary neuroblastomas, nor could we restore ZNF423 levels in neuroblastoma cell lines with low ZNF423 by DNA-demethylating agents. These results indicate that ZNF423 expression is determined by transcriptional regulation, rather than by epigenetic silencing or genetic loss. The signaling pathways that regulate ZNF423 expression could therefore be the critical components governing the RA response.
As pointed out above, the overall response rate to RA in neuroblastoma patients is low, suggesting that only a subgroup of patients benefits from the treatment. Currently, no predictive markers of RA responsiveness are available for clinical use. No alterations in any of the core components of the RA signaling pathway have been described in neuroblastoma tumors, posing a conundrum of how to explain the diversity in RA sensitivity. To gain more mechanistic insights into the factors that control RA responsiveness in neuroblastoma, we performed an unbiased large-scale RNAi screen in neuroblastoma cells. We identify here the tumor suppressor NF1 as a major determinant of RA sensitivity in neuroblastoma cells and find genetic alterations in NF1 in primary tumors and neuroblastoma cell lines. We provide proof-of-concept experiments for a therapeutic strategy to overcome RA resistance in NF1-deficient neuroblastomas by the coapplication of RA with MEK inhibitors.
RESULTS

NF1 Suppression Confers Resistance to RA in Neuroblastoma
In response to RA, the human neuroblastoma cell line SH-SY5Y ceases proliferation and differentiates into neuronal-like cells. To identify novel determinants of RA resistance in neuroblastoma, we performed a large-scale RNAi-based loss-of-function genetic screen using a collection of 24,000 short-hairpin (shRNA) vectors targeting 8000 human genes (Berns et al., 2004) . We used a barcoding technology to identify genes whose suppression causes resistance to RA (Brummelkamp et al., 2006) . The entire shRNA library was introduced into SH-SY5Y cells by retroviral infection and cells were plated at low density with or without RA ( Figure 1A ). After 4 weeks of RA selection, genomic DNA was isolated from both cultures. The stably integrated shRNA cassettes (19-mer barcode sequences) were recovered by PCR. The relative abundance of individual shRNA vectors was quantified by hybridization of the PCR products to microarrays harboring all 24,000 barcode sequences. The barcode screen was carried out in triplicate and the results are shown in Figure 1B . Each dot in the M/A plot represents one individual shRNA vector in the library. M and A values reflect relative enrichment and hybridization signal intensity. Reproducible outliers are generally located in the right upper corner. Lowintensity spots are prone to technical artifacts and thus unreliable. Therefore we restricted our candidate selection by applying M/A cut-off values as indicated in Figure 1B . To rule out ''offtarget'' effects, we only consider a gene identified from the screen as a genuine hit if at least two independent shRNAs suppress the expression of the target and also confer RA resistance. Within the list of 44 candidate hits fulfilling the cut-off criteria, the only gene that was represented by two shRNAs was the tumor suppressor gene NF1 (neurofibromin 1), and it was thus studied further.
To validate the results of the screen, we individually introduced into SH-SY5Y cells the two NF1 shRNAs (#1 and #2) from the library and one newly generated (#3). Vectors targeting GFP (shGFP) or harboring only the empty vector (pRS) served as controls throughout the study. All three NF1 knockdown vectors conferred resistance to RA in long-term colony formation assays and efficiently suppressed NF1 mRNA and protein expression ( Figure 1C) . We also noted a growth advantage of NF1 knockdown cells in the absence of exogenously added RA. This may result from resistance to low levels of RA present in the culture medium or from an RA-independent proliferation advantage. Therefore, we used the 3T3 protocol to perform a long-term proliferation assay of SH-SY5Y cells expressing shRNAs against NF1, GFP, or control vector (pRS) ( Figure 1D ). A slightly increased growth rate of NF1 knockdown cells was indeed detected in the absence of exogenous RA. However, when exposed to RA, shNF1-expressing cells continued to proliferate, whereas control cells completely ceased proliferation after a latency of about 10 days and the total cell number even declined, indicating that prolonged RA treatment caused cell death of the control cells. Thus, NF1 knockdown cells are clearly rescued from RA-mediated differentiation and growth arrest. Identical results were obtained in other neuroblastoma cell lines having different levels of MYCN amplification (SK-N-SH, SJ-NB6, Kelly, HT-230, and LAN-5; Figure S1 available online and data not shown), indicating that NF1 knockdown can cause resistance to RA independent of MYCN amplification status in a range of neuroblastomas.
RAS Signaling Linked to RA Response
It has been found that the neuroblastoma cell line SJ-NB-10 (NB90-9) harbors a homozygous deletion of some exons of the NF1 gene, suggesting that these cells could be insensitive to RA (The et al., 1993) . Figure 2 shows that SJ-NB-10 cells indeed lack NF1 mRNA and protein ( Figure 2A ) and fail to respond to RA ( Figure 2B ). NF1 is a large protein that has GTPase-activating activity (GAP) and functions as a negative regulator of RAS proteins by promoting their conversion from the active GTPbound to the inactive GDP-bound form (Cichowski and Jacks, 2001; Martin et al., 1990) . Loss of NF1 expression results in hyperactive RAS signaling, and therefore we reasoned that hyperactive RAS signaling could cause RA resistance in this NF1-deficient neuroblastoma cell line.
We stably introduced the GAP-related domain of NF1 (NF1-GRD) into the NF1-deficient SJ-NB-10 cells. Expression of the NF1-GRD is widely used to restore NF1-dependent GAP activity and thus inhibition of RAS activity in cells lacking NF1 (Martin et al., 1990) . Expression of the NF1-GRD was determined by qRT-PCR using NF1-GRD-specific primers ( Figure 2D ). SJ-NB-10 cells expressing NF1-GRD were exquisitely sensitive to RA, and cell growth was impaired by almost 7-fold relative to the control cells. In the absence of RA, however, the inhibition was only 2.5-fold, underscoring the RA-specific sensitization effect ( Figure 2C ).
Our results suggest that hyperactive RAS signaling is responsible for the RA resistance associated with a naturally occurring Human shRNA library polyclonal virus was produced to infect SH-SY5Y cells, which were then left untreated (control) or treated with 100 nM all-trans retinoic acid (RA). After 4 weeks of selection, shRNA inserts from both populations were recovered, labeled, and hybridized to DNA microarrays as described (Brummelkamp et al., 2006 Figure 2F ) oncogene can cause RA resistance in sensitive SH-SY5Y cells. Similar to NF1 knockdown, cells expressing the KRAS oncogene potently bypassed RA-induced growth arrest ( Figure 2E ).
To investigate the role of endogenous KRAS in the RA resistance caused by NF1 loss, we performed an epistasis analysis. SH-SY5Y cells were simultaneously infected with shRNAs against KRAS and NF1. Suppression of KRAS ( Figure 2H ) in combination with NF1 impaired the occurrence of RA-resistant cells driven by NF1 knockdown, whereas cells coinfected with shNF1 and pRS were highly resistant to RA ( Figure 2G ). This indicates that KRAS is critically required to mediate the effects of NF1 knockdown on the RA response.
NF1 Loss Inhibits Transcriptional Response to RA RA exerts its biological effects largely through gene regulation. We therefore addressed whether suppression of NF1 interferes with the transcriptional response to RA. ShRNAs targeting NF1 or GFP were cotransfected with a reporter gene containing a consensus RARE linked to luciferase (RARE-Luc). Both shRNAs against NF1 inhibited the reporter gene activation by RA ( Figure 3A) . Moreover, NF1 knockdown also suppressed expression of bona fide endogenous RA target genes RARb, CRABP2, and TGM2 ( Figures 3B-3D ). Similarly, exogenous expression of KRAS V12 also repressed RA-dependent target gene activation. Similar results were obtained in other neuroblastoma cell lines (data not shown). These results further suggest that hyperactive RAS signaling downstream of NF1 blocks the transcriptional response to RA in neuroblastoma cells. Transcriptional induction of the RET tyrosine kinase, a gene associated with neuroblastoma differentiation (Bunone et al., 1995) , was consistently blocked in shNF1-and KRAS V12 -expressing cells, indicating that NF1 suppression overrides not only proliferation arrest but also differentiation induced by RA ( Figure 3E ).
NF1 Loss Downregulates the RAR/RXR Coactivator ZNF423
As cofactors are critical determinants of RAR/RXR transcriptional activity, we asked whether modulation of a cofactor(s) might play a role in the RA resistance caused by NF1 knockdown. Global gene expression analysis in NF1 knockdown cells identified 196 and 167 genes that were greater than 2-fold up-or downregulated (Table S1) . Among these genes, we found the RAR/RXR coactivator ZNF423 to be significantly repressed in shNF1-expressing cells. We have previously shown that ZNF423 physically interacts with RAR/RXR heterodimers and binds to RA-responsive promoters (Huang et al., 2009 Figures  S2A-S2D ).
To address whether suppression of ZNF423 is causal for the RA resistance of NF1 knockdown cells, we re-expressed ZNF423 at physiological levels in shNF1-expressing SH-SY5Y cells ( Figures 4C and 4D) . Reconstitution of ZNF423 was capable of partially restoring responsiveness to RA in otherwise insensitive NF1 knockdown cells ( Figure 4C ). In line with our previous study, ZNF423 expression caused hypersensitivity to RA along with a moderate inhibition of proliferation ( Figure 4C ). ZNF423 reconstitution in NF1 knockdown cells also restored expression of bona fide RA target genes, such as TGM2 and CRABP2 ( Figures 4E  and 4F ). Our results demonstrate that ZNF423 is a major, but possibly not the only, component downstream of NF1 in the control of RA sensitivity in neuroblastoma cells.
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ZNF423 Predicts RA Responsiveness
As NF1 loss causes resistance to RA, at least in part, by suppression of ZNF423, our data raise the possibility that ZNF423 levels might predict sensitivity of neuroblastomas to RA. To begin to address this, we explored the predictive value of ZNF423 expression for RA responsiveness in a panel of 26 different neuroblastoma cell lines. We investigated the sensitivity to RA (100 nM) by long-term colony formation assays. The response to RA was determined by the relative growth of treated versus untreated cultures. ZNF423 mRNA levels were measured by qRT-PCR in the absence of RA ( Figure 4G and Figures S2E and S2F) . The response to RA ranged from highly sensitive to fully resistant. High expression of ZNF423 was significantly associated with sensitivity to RA (Spearman correlation, p = 0.01). The range of ZNF423 expression within the cell line panel was comparable to the regulation observed by knockdown of NF1 in SH-SY5Y and other neuroblastoma cell lines ( Figure 4A , Figure S2E ). This underscores the functional relevance of ZNF423 suppression by knockdown of NF1.
NF1 Expression Predicts Outcome of Neuroblastoma
We have shown previously that ZNF423 expression is prognostic for event-free survival of neuroblastoma patients (Huang et al., 2009) . Given the functional connection between NF1 and ZNF423, we investigated a possible prognostic significance of NF1 expression in neuroblastoma by microarray analysis in three independent patient cohorts. The first cohort consists of 88 neuroblastoma patients from the Academic Medical Center (AMC) in Amsterdam, Netherlands (Huang et al., 2009) . We used this cohort as a ''training set'' to generate an optimal cutoff value of NF1 expression by a Kaplan scanning approach (see Experimental Procedures for details). Patients were then classified into NF1 low or high based on their NF1 levels in the primary tumors using this cut-off value, and progression-free survival was assessed by Kaplan-Meier analysis. The NF1 high subgroup had a significantly better outcome than the NF1 low subgroup ( Figure 5A ). Similar results were obtained with median expression (p = 0.028) or average expression (p = 0.017) as cut-off values for NF1 expression. Importantly, NF1 retains prognostic significance in combination with any of the four clinically used prognostic markers: MYCN amplification, deletion of chromosomal band 1p36 (LOH 1p36), age (<18 months), and stage in a multivariate analysis (Table S2) .
We then validated the prognostic value of NF1 expression in an independent cohort of 102 neuroblastoma patients from the Childrens Hospital Los Angeles (CHLA) with metastatic tumors lacking MYCN amplification, for which progression-free survival data are known (Asgharzadeh et al., 2006) . Because the same microarray platform was used, the NF1 expression from both datasets was normalized and the cut-off value used in AMC series was applied to the validation cohort. Again, high level of NF1 expression correlated with longer progression-free survival protein levels are also reduced n NF1 knockdown cells. See also Figure S2 and Table S1 . Figure S2 . and in return low NF1 expression was associated with poor outcome ( Figure 5C ). When we combined the expression status of NF1 and ZNF423, patients classified as NF1 low /ZNF423 low had the poorest disease outcome, whereas the NF1 high /ZNF423 high groups had the best outcome ( Figures 5B and 5D ). High expression of either NF1 or ZNF423 alone was correlated with an intermediate progression-free survival. As the CHLA validation cohort was restricted to a subset of high-risk tumors without MYCN amplification, we analyzed a third independent dataset that covers all stages including MYCN-amplified tumors (Oberthuer et al., 2006) . These gene expression data were generated on a different microarray platform. Therefore, we randomly divided the entire cohort into a training set (n = 125) and validation set (n = 126), and cut-off values for NF1 and ZNF423 were determined as described above in the training set and then applied to the validation set. Again, low expression of NF1 and ZNF423 Figure  5 . NF1 Expression Predicts Outcome of Neuroblastoma, and the Combined Expression Status of NF1 and ZNF423 is a Powerful Prognostic Marker (A) Kaplan-Meier analysis of the AMC cohort (n = 88) documenting increased progression-free survival (PFS) of neuroblastoma patients with tumors that have high NF1 expression (NF1 high) versus patients with tumors that have low NF1 expression (NF1 low), using the NF1 cut-off value determined as described in the text. See also Table S2 . (B) Kaplan-Meier analysis of PFS for the AMC cohort classified by the combined expression status of NF1 and ZNF423. The NF1 cut-off value was the same as above and ZNF423 cut-off value was as described previously (Huang et al., 2009 ). (C) Kaplan-Meier analysis of PFS for a second independent set of 102 patients from CHLA diagnosed with metastatic neuroblastomas lacking MYCN amplification (Asgharzadeh et al., 2006) . These patients were classified using the same NF1 cut-off value determined from the AMC cohort. correlated with poor outcome ( Figure 5E and data not shown). When we combined NF1 and ZNF423 expression, patients classified as NF1 low /ZNF423 low had the poorest disease outcome, whereas the NF1 high /ZNF423 high group had the best outcome ( Figure 5F ). Prognostic significance of NF1 and the combined NF1/ ZNF423 expression status were independent of MYCN amplification in a multivariate analysis (Table S2) . Differences in progression-free survival were consistent and statistically significant in all three patient cohorts. Moreover, the ZNF42 low group was significantly enriched for NF1 low tumors (Wilcoxon test, p < 0.001 in all three cohorts). This is in line with the functional interaction between NF1 and ZNF423 that we observed in cell lines. In summary, the combined expression status of the two functionally connected genes, NF1 and ZNF423, is a powerful prognostic marker in neuroblastoma.
NF1 Mutations in Neuroblastoma
Most of the patients with neurofibromatosis type 1 harbor mutations of the NF1 gene, ranging from single point mutations to larger deletions (Messiaen et al., 2000; Wimmer et al., 2006; Zatkova et al., 2004) . NF1 mutations and deletions were also found in 23% of glioblastomas, a highly aggressive adulthood brain tumor (TCGA_Network, 2008) . A role for NF1 in the pathogenesis of neuroblastoma has been discussed based on cell line observations but never studied systematically in a large cohort of primary neuroblastomas (The et al., 1993) . In a panel of 25 neuroblastoma cell lines, we found loss of NF1 protein expression in approximately one third ( Figure 6A ). Absence of NF1 protein was significantly associated with resistance to RA and also lower expression of ZNF423 ( Figure S3 ). An overview of genomic defects of NF1 was obtained by a comprehensive single-nucleotide polymorphism (SNP) analysis (Illumina 657K platform) in 20 neuroblastoma cell lines (Figure 6B) . We detected homozygous microdeletions in SJ-NB10 (NB90-9) and SK-N-FI cells, deleting part of NF1 or NF1 and a neighboring gene (Figures S4A and S4B) . The cell line GI-ME-N showed a 3.6 Mb hemizygous deletion encompassing NF1, whereas the second NF1 allele had a microdeletion. AMC106 and SK-N-AS cells showed hemizygous deletions of the NF1 region of 3.7 and 5.4 Mb. Five more cell lines (NMB, N206, SK-N-BE, UHGNP, and SJ-NB8) showed loss of heterozygosity encompassing the NF1 region. Only 10/20 cell lines had two apparently normal NF1 alleles. These results urged us to screen for mutations of NF1 in the AMC patient cohort that covers a representative spectrum of neuroblastoma and ganglioneuroma cases including different disease stages, ages, and MYCN amplifications. Sequencing of the full coding region in cDNA identified two mutations, which were both confirmed by sequencing of the genomic exons ( Figure 6C) . One neuroblastoma carried a 5 base pair deletion in exon 34 inducing a frameshift. A ganglioneuroma was detected with a missense mutation in exon 15, which is also known from neurofibromatosis type 1 patients (Griffiths et al., 2007) . Reanalysis of the clinical records revealed that the patient in our series was indeed diagnosed with neurofibromatosis type 1. Sequencing of the exonic DNA of this tumor revealed that besides the mutated allele, also a normal NF1 allele was present. However, at the cDNA level, only expression of the mutant allele was observed, suggesting epigenetic silencing of the normal NF1 allele (Figure S4C) . Finally, we performed an SNP analysis of 50 neuroblastoma patients from the AMC series. This identified one tumor with a 390 kb heterozygous deletion covering NF1, as well as two tumors with translocations involving chromosome 17 with breakpoints in NF1, resulting in gain of distal chromosome 17q starting in NF1 ( Figure 6C ). We conclude that NF1 aberrations are detected in primary neuroblastomas, but at lower frequency than in neuroblastoma cell lines.
Restoration of RA Responsiveness RA maintenance therapy has a modest, but significant, benefit for high-risk neuroblastoma patients. Our results suggest that tumors with activated RAS signaling, e.g., by NF1 loss/mutation and low expression of ZNF423, would respond poorly to RA. We reasoned that inhibitors of downstream components of RAS could potentially restore sensitivity to RA in these tumors. To address this concept, we first dissected the contribution of the major RAS downstream effector pathways by expressing respective active alleles. BRAF V600E and MEK-DD conferred resistance to RA, in contrast to PIK3CA H1047R , RALA Q75L , and RALB Q72L ( Figure 7A) . Noteworthy, the activation of AKT by PIK3CA H1047R was comparable to that by KRAS V12 ( Figure 7B ).
Even expression of highly active myristylated AKT failed to potently rescue cells from RA-mediated growth arrest. Further, only KRAS V12 , BRAF
V600E
, and MEK-DD blocked RA target gene activation ( Figure 7C) . Therefore, the RAF-MEK cascade is the predominant pathway responsible for resistance to RA by NF1 loss in neuroblastoma cells. . SH-SY5Y cells expressing pBabe vector control or the indicated active alleles of RAS effector pathways were cultured for 12 and 20 days in the absence or presence of 1 mM RA and then fixed, stained, and photographed. (B) Level of phosphorylated ERK and AKT in the SH-SY5Y cells described in Figure 7A . (C) Activation of the RA target gene TGM2 in SH-SY5Y cells described in Figure 7A . Cells were grown for 14 days in the absence or presence of 1 mM RA. (D) MEK inhibition restores RA sensitivity in NF1 knockdown cells. SH-SY5Y cells expressing shGFP control or shNF1 were grown in the absence or presence of 1 mM RA for 13 and 18 days. Cells were additionally treated with or without the MEK inhibitor U0126 at various concentrations. Cells were then fixed, stained, and photographed. (E-G) Inhibition of MEK signaling and re-expression of ZNF423 and TGM2 in NF1 knockdown cells treated with MEK inhibitor U0126. SH-SY5Y cells expressing shGFP control or shNF1 grown in the presence of 1 mM RA for 9 days and then additionally treated with or without U0126 for 2 days. Levels of phosphorylated ERK were detected by western blotting (E). ZNF423 and TGM2 mRNA expression was determined by qRT-PCR. Error bars denote SD. **p < 0.001 (t test for comparison of three biological independent experiments). See also Figure S5 .
Next, we added increasing concentrations of the MEK inhibitor U0126 with or without RA to SH-SY5Y cells expressing either shGFP or shNF1 ( Figure 7D ). Addition of U0126 restored sensitivity to RA in NF1 knockdown cells that were otherwise resistant. Application of U0126 affected cell growth only moderately in the absence of RA. Importantly, MEK inhibition partially restored ZNF423 expression and subsequently RA target gene expression in NF1 knockdown cells and also other NF1 low neuroblastoma cell lines ( Figures 7E-7G and Figure S5 ). Thus, the combination of RA and a MEK inhibitor might be a valid strategy for the maintenance therapy of high-risk neuroblastoma, in particular for tumors with low or mutated NF1.
DISCUSSION
Through an unbiased large-scale RNAi screen in neuroblastoma cells, we identify here an unexpected role in RA signaling for the tumor suppressor NF1. The NF1 protein is known to antagonize activation of RAS proteins, but it has also been implicated in other pathways such as cAMP/PKA signaling (Tong et al., 2002) .
In this study, we provide several lines of evidence that NF1 controls the response to RA in neuroblastoma through the RAS-MEK signaling cascade. We identify here a mechanistic connection between NF1-RAS-MEK and RA signaling by showing that the NF1-RAS-MEK cascade suppresses expression of the RAR/RXR coactivator ZNF423 (Figures 4A and 4B and Figure 7B) . We have shown recently that ZNF423 is critically required for the response to RA in neuroblastoma (Huang et al., 2009 Other studies have also suggested a role for MAPK signaling in regulation of responses to RA in different cellular systems (Antonyak et al., 2003; Bruck et al., 2009; Delaune et al., 2008; Gianni et al., 2006; Kosa et al., 1995; Quinlan et al., 2008; Verheijen et al., 1999) . These data indicate that the effects of MAPK signaling on RA responses can be heterogeneous. This may be explained by cell type-specific regulatory mechanisms. Indeed, RARs can use a multitude of coactivators, some of which are cell type specific, including ZNF423. Moreover, there is evidence that short-term responses to MAPK signaling are quite distinct from the long-term effects we studied here. For example, p38MAPK activates RAR signaling by phosphorylation of RARa by MSK1, a p38MAPK-activated kinase, but also inhibits RAR signaling later by phosphorylation and degradation of the RARa coactivator SRC3 (Gianni et al., 2006) . However, a role for the p38MAPK pathway in RA-mediated long-term growth arrest in neuroblastoma has not been established.
Given that RA plays a central role in neuronal differentiation and that Rara-knockout mice exhibit neural crest defects (McCaffery et al., 2003) , we reasoned that NF1 expression could potentially impact the clinical course of neuroblastoma and even act as a tumor suppressor in human neuroblastoma. In three independent gene expression datasets of 316 neuroblastoma patients in total, we found that low expression of NF1 (NF1 low ), in particular in combination with ZNF423 low , correlated with a very poor outcome ( Figure 5 ). Tumors having both NF1 low and ZNF423 low constitute a clinically significant subgroup. In contrast, high expression of both was associated with the best prognosis. NF1 low tumors were significantly enriched in the ZNF423 low subgroup, suggesting that hyperactive RAS-MEK signaling also contributes to suppression of ZNF423 in primary neuroblastomas. Proteasomal degradation of NF1, as observed in glioblastoma, could also account for active RAS signaling and suppression of ZNF423 (McGillicuddy et al., 2009) . As RAS mutations occur rarely if ever in primary neuroblastoma, other negative or positive regulators of RAS signaling could be involved as well. In addition, control of ZNF423 level by independent signaling pathways could antagonize or synergize with RAS signaling.
Germline mutations in NF1 are linked to neurofibromatosis type 1, and somatic mutations and deletions are frequent in glioblastoma (Messiaen et al., 2000; TCGA_Network, 2008) . The data demonstrating the poor prognosis of patients with NF1 low expression sparked our interest in asking if NF1 could also be lost by mutation in neuroblastoma. We found two sequence mutations and three genomic aberrations (microdeletion, 17q duplication) in the NF1 gene out of 83 analyzed tumors. Based on a few incidental case reports, a predisposition of neurofibromatosis type 1 patients for neuroblastoma has been proposed (Martinsson et al., 1997; Origone et al., 2003) . Indeed, the identified H553R missense mutation in NF1 proved to be a neurofibromatosis type 1-associated germline mutation. The germline status is unknown for the other patient having a five base pair deletion in NF1. Remarkably, this patient was diagnosed as stage 2 disease, which in general has an excellent prognosis. Nevertheless, this patient was the only one of the 23 stage 1/2 neuroblastoma patients in the AMC cohort that died of disease.
The mutation rate of NF1 in neuroblastoma was lower than reported for glioblastoma. It is reasonable to expect fewer mutations in an embryonal tumor-like neuroblastoma than in a highly genomic unstable and largely p53-deficient adulthood malignancy. In addition, low-and intermediate-risk neuroblastomas (50% of the AMC cohort) have a very good disease outcome, and because low expression of NF1 correlated with poor outcome, we speculate that NF1 mutations are more prevalent in high-risk disease. However, larger cohorts will be required to investigate this hypothesis.
In conclusion, we found genomic aberrations of the NF1 gene in 6% (5/83) of primary neuroblastomas, supporting a direct role for NF1 in the pathogenesis of the disease, at least in a subset of cases. Noteworthy, activating mutations in the protein-tyrosine phosphatase PTPN11 (SHP2), an enhancer of RAS signaling, have been previously described in 3.4% (3/89) of neuroblastomas (Bentires-Alj et al., 2004) . Dominant mutations in PTPN11 cause the developmental disorder Noonan syndrome and possibly predispose to neuroblastoma (Cotton and Williams, 1995; Tartaglia et al., 2001) . Together with our functional, mutational, and survival studies on NF1, these results further substantiate a role for aberrant RAS signaling in the development of neuroblastoma, even though RAS mutations are rarely, if ever, found in this type of cancer (Moley et al., 1991) .
Our data predict that low levels of ZNF423 and NF1 will be associated with poor response to RA-based therapies in the clinic. To begin to address this, we asked if we could observe a correlation between ZNF423 levels and RA responsiveness in a panel of 26 neuroblastoma cell lines. We reasoned that loss of NF1 causes suppression of ZNF423 expression (Figures 4A and 4B) and hence that ZNF423 levels would also report NF1 status in neuroblastoma cell lines. Indeed, we found that high expression of ZNF423 significantly correlated with sensitivity to RA ( Figure 4E ). The range of ZNF423 expression in the cell line panel corresponds well to the 3-to 4-fold repression of ZNF423 caused by loss of NF1.
RA is used as a maintenance therapy with some success for high-risk neuroblastoma, and levels of NF1 and/or ZNF423 may well account for at least a fraction of nonresponders in the clinic. Our finding that MEK inhibitors can restore responsiveness to RA in vitro in NF1 low cells suggests a potential strategy to improve the therapeutic efficacy of retinoids in the treatment of neuroblastoma. As highly selective MEK inhibitors are currently evaluated in clinical trials, their combination with RA could be an attractive therapeutic approach.
Most, if not all, established predictive biomarkers for targeted therapies affect the target itself or key downstream components of the signaling pathway targeted by the drug. For example, KRAS mutations confer resistance to epidermal growth factor receptor (EGFR)-targeted therapy in colon cancer, and PIK3CA mutations or lack of PTEN expression correlate with poor response to trastuzumab in HER2-positive breast cancer (Berns et al., 2007; Karapetis et al., 2008) . Our results reveal a paradigm for predictive biomarkers by demonstrating that aberrant activity of lateral signaling pathways can determine the response to a targeted therapeutic without mutations in any of the core components of the pathway itself. Our data highlight the importance of mapping crosstalk between signaling pathways to predict responses to targeted therapies in cancer. Unbiased genetic screens are powerful tools to identify these genetic interactions, and the present case even suggests a therapeutic strategy to restore drug response in resistant patients.
EXPERIMENTAL PROCEDURES
shRNA Barcode Screen The NKI shRNA library and the barcode screen are as described (Berns et al., 2004; Brummelkamp et al., 2006) . Additional details can be found at http:// screeninc.nki.nl/.
Cell Proliferation Assays
Single-cell suspensions were seeded into 6-well plates (1-2 3 10 4 cells/well) and cultured both in the absence and presence of RA. At the endpoints of colony formation assays, cells were fixed, stained with crystal violet, and photographed. All knockdown and overexpression experiments were done by retroviral infection. For the experiments to measure RA responsiveness in the panel of 26 neuroblastoma cell lines, each line was subjected to longterm colony formation assays in triplicates in the absence or presence of 100 nM RA. Treated and untreated dishes of each cell line were harvested at the same time. Crystal violet stain was then extracted using 10% acetic acid and quantified at optical density (OD) 590 nm. The growth curves were performed according to the standard 3T3 protocol. All relevant assays were performed independently at least three times.
Patient Samples
For all studies presented, the expression data were obtained using Affymetrix microarray analyses on the untreated primary tumor samples at the time of diagnosis. The patient samples for both cohorts and the definition of an event (progression-free survival) for both cohorts are as described (Asgharzadeh et al., 2006; Huang et al., 2009 ). Written informed consent was obtained from patients' parents or guardians in accordance with institutional review board policies and procedures for research dealing with tumor specimen and clinical information. The institutional review board at Childrens Hospital Los Angeles (CHLA) and the medical-ethics committee of the Academic Medical Center (AMC) in Amsterdam approved the study.
Statistical Analysis
To determine the optimal value to set as a cut-off for NF1 expression in the AMC cohort, kaplan scanning was used as described for the cut-off for ZNF423 (Huang et al., 2009 ). The cut-off value was validated using a second independent set of 102 CHLA patients (Asgharzadeh et al., 2006 
